|
Available in print and online, BioCommerce Data's European Biotechnology Directory provides in-depth information on the biotechnology industry across Europe. It is a great resource to help you in your daily job, whether you are looking for a partner; new markets for your products; financial backing; commercial or academic support; or contract services. Fully researched and updated for 2005, it features detailed profiles of 1,800 biotechnology companies and 800 allied organisations from venture capitalists, to academic institutions and development agencies, complete with contact information, financial history and details of products and services and interest areas. Find out more about BioCommerce Data by calling Sarah Walkley on +44 (0)20 7017 4147 or email: sarah.walkley@informa.com |
 |
|
BioVenture View is essential reading for anyone concerned with the issues affecting today’s biotech industry. With its particular focus on privately held R&D drug developers, our twice-monthly newsletter brings you intelligence on company deals, mergers and acquisitions, financing events, and product development. Combining in-house expertise with its network of industry contacts, BioVenture View also provides inside news and expert opinions on all the significant trends, so you can stay at the forefront of the latest movements and innovations that are shaping the market. Find out more about BioVenture View at www.bioventureview.com. Alternatively, you can call Nicholas Johnston on +44 (0)20 7017 6861 or email: nicholas.johnston@pjbpubs.com . |
 |
|
Founded in 1998 GoingPublic Media AG is today one of the leading companies in Germany publishing magazines on venture capital and corporate finance contents as well as small and mid cap research. In addition to the monthly issued GoingPublic Magazin and its well known yearly special editions like “Corporate Finance & Private Equity Guide”, “Biotechnology “or “Investor Relations” which are largely meant as reference books, the company publishes the likewise monthly VentureCapital Magazin. Founded in 2000 as a supplement to the GoingPublic Magazin, VentureCapital Magazin (www.venturecapital.de) started into a new era as an independent publication in July 2002 and focuses on private equity, buy-outs and M&A. The brand is a synonym for growth, innovation, entrepreneurial culture and equity financing. Special topics are additionally treated in supplements and special editions (“Nanotechnology”, “Mittelstandsfinanzierung” etc). Furthermore GoingPublic Media operates the online-service GoingPublic Online (www.goingpublic.de) and the corporate publishing division (GoingPublic Services) publishes about 10 magazines and newsletters a year for well-known venture capital companies and financial institutions. Since May 2003 the company publishes a third magazine called “Smart Investor” (www.smartinvestor.de). With its critical research and independent thinking, Smart Investor is an ambitious, fast growing magazine for the contrarian investor seeking information beyond the mainstream. All publications are printed in German. Contact: Orders and subscriptions: For more information, please contact us at +49-8171-419650 or info@goingpublic.de |
|
| The Journal of Biolaw & Business Grow your business with The Journal of BioLaw & Business! The Journal of BioLaw & Business is the leading international publication established in 1997 to address emerging legal, business, scientific and regulatory issues impacting the growth of the biotechnology, life science and investment sectors. BioLaw's world-class expert advisory board, educational supporters and authors provide original substantive analyses, and valuable practical tools and guidance to biotechnology and life science executives, attorneys, biomedical researches, entrepreneurs, licensing and tech transfer specialists, investors and policy-makers. Special thematic BioLaw & Business Supplements (on topics such as licensing, intellectual property, bioinformatics, and venture financing) can also be ordered separately. On-line full text access is available to subscribers and member sites. Published quarterly, with topic-specific supplements
and electronic updates, BioLaw offers timely reporting, thoughtful
analysis, case studies and practical solutions to present issues
and future concerns in these emerging fields. It is designed for
those who want to stay ahead of rapidly changing innovations. BioLaw's
distinguished advisors and authors offer "real world"
perspectives and the practical tools necessary to meet the sectors'
unique challenges. |
|
|
Rx Communications is a financial communications firm specializing in the life science and healthcare industries. Rx provides investor relations, media relations and corporate communications counsel to private and public companies, worldwide. The firm designs, implements and manages full-service programs, as well as transaction-oriented assignments. Rx is well versed in IPOs, secondary offerings, PIPEs, venture rounds and mergers and acquisitions - all complementing the on-going work Rx performs on behalf of clients. RxIR USA® is a service of Rx Communications geared toward non-U.S. listed public foreign companies seeking to reach U.S. investors. |
|
|
The Ruth Group (TRG) is a boutique communications agency, which combines sound counsel with creative solutions. Our integrated investor relations and public relations programs are built on a foundation of specialized healthcare experience and seasoned professionals. Our healthcare team has the scientific expertise and understanding to effectively manage a wide range of companies and the industry experience to leverage this background for our clients. TRG’s international roster of healthcare clients includes biotechnology, biopharmaceutical, diagnostic, discovery and medical device companies. Our goal is to deliver results that match our clients' business strategy, capital needs and competitive environment. |
|